Safety and tolerability results of the GATTO study, a phase Ib study combining the anti-TA-MUC1 antibody gatipotuzumab with the anti-EGFR tomuzotuximab or panitumumab in patients with refractory solid tumors.

Elena Garralda,Gianluca Del Conte,M. Macchini,Ignacio Matos,Konrad Klinghammer,Omar Saavedra Santa Gadea,Walter Fiedler,Christina C Rolling,Maxim Kebenko, Francesco Raspagliesi,Domenica Larusso,Isabelle ahrens-Fath,Beate Habel,Hans Baumeister,Alfredo Zurlo,Sebastian Ochsenreither

Journal of Clinical Oncology（2021）

引用 2|浏览16

暂无评分

摘要

2522Background: The phase I GATTO study explored the feasibility, tolerability and preliminary activity of combining Gatipotuzumab (GAT), a novel humanized monoclonal antibody binding to the tumor-...

查看译文

关键词

panitumumab,refractory solid tumors,gatto study,anti-ta-muc,anti-egfr

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要